IZOTEX 20 - Euro-Pharmacies

While Accutane (isotretinoin) stands out for its high success rate in treating severe acne, it also presents a risk profile requiring substantial caution. The FDA implemented the iPLEDGE program in 2005 to manage these risks, especially teratogenicity, which has made Accutane a regulated, last-resort choice in dermatology. The program mandates stringent birth control and education for female patients to prevent pregnancy during treatment. Compared to other acne therapies, Accutane’s strict requirements underscore the need for careful adherence to minimize risks​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about IZOTEX 20 by Euro-Pharmacies, consult with your doctor or healthcare professional.